Standout Papers

An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacte... 2007 2026 2013 2019 4.1k
  1. An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases (2007)
    David E. Griffith, Timothy R. Aksamit et al. American Journal of Respiratory and Critical Care Medicine
  2. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis (2014)
    Sofía Ramiro, C. Gaujoux-Viala et al. Annals of the Rheumatic Diseases
  3. The emerging safety profile of JAK inhibitors in rheumatic disease (2017)
    Kevin Winthrop Nature Reviews Rheumatology
  4. Neutralizing monoclonal antibodies for treatment of COVID-19 (2021)
    Peter C. Taylor, Andrew C. Adams et al. Nature reviews. Immunology
  5. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary (2015)
    R. Andrés Floto, Kenneth N. Olivier et al. Thorax
  6. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis (2015)
    R. Andrés Floto, Kenneth N. Olivier et al. Thorax
  7. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials (2017)
    Stanley Cohen, Yoshiya Tanaka et al. Annals of the Rheumatic Diseases
  8. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme (2020)
    Stanley Cohen, Ronald van Vollenhoven et al. Annals of the Rheumatic Diseases
  9. Oral surveillance and JAK inhibitor safety: the theory of relativity (2022)
    Kevin Winthrop, Stanley Cohen Nature Reviews Rheumatology
  10. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis (2023)
    Gerd R Burmester, Stanley Cohen et al. RMD Open

Immediate Impact

9 from Science/Nature 57 standout
Sub-graph 1 of 18

Citing Papers

A natural experiment on the effect of herpes zoster vaccination on dementia
2025 StandoutNature
Framework Nucleic Acid-Based and Neutrophil-Based Nanoplatform Loading Baicalin with Targeted Drug Delivery for Anti-Inflammation Treatment
2025 Standout

Works of Kevin Winthrop being referenced

The role of IL-6 in host defence against infections: immunobiology and clinical implications
2017
Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination
2016

Author Peers

Author Last Decade Papers Cites
Kevin Winthrop 10418 5885 7910 399 21.8k
Olivier Lortholary 15479 853 15904 473 22.8k
Javier P. Gisbert 7073 826 1808 869 28.8k
Phillip Scott 16987 1462 1500 251 31.2k
Jay K. Kolls 8319 2016 5695 467 40.1k
Sander J. H. van Deventer 7651 1444 1786 267 21.8k
Frank L. van de Veerdonk 5954 599 6306 234 17.7k
Robert L. Modlin 10172 1023 9751 351 37.7k
Lionel Rostaing 5154 512 3515 581 19.7k
Hermann Einsele 8615 468 6095 748 28.9k
Dimitrios P. Kontoyiannis 23942 269 28858 600 37.6k

All Works

Loading papers...

Rankless by CCL
2026